Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Minority Interest (2016 - 2025)

Historic Minority Interest for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$1.2 million.

  • Lineage Cell Therapeutics' Minority Interest rose 1063.22% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year increase of 1063.22%. This contributed to the annual value of -$1.4 million for FY2024, which is 193.41% up from last year.
  • Lineage Cell Therapeutics' Minority Interest amounted to -$1.2 million in Q3 2025, which was up 1063.22% from -$1.3 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Minority Interest high stood at -$1.1 million for Q1 2021, and its period low was -$1.5 million during Q3 2023.
  • For the 5-year period, Lineage Cell Therapeutics' Minority Interest averaged around -$1.3 million, with its median value being -$1.4 million (2025).
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Minority Interest soared by 3658.82% in 2021, and later tumbled by 2422.08% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Minority Interest (Quarter) stood at -$1.3 million in 2021, then dropped by 6.05% to -$1.4 million in 2022, then increased by 0.5% to -$1.4 million in 2023, then grew by 1.93% to -$1.4 million in 2024, then grew by 9.13% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, -$1.3 million for Q2 2025, and -$1.4 million during Q1 2025.